A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis

Journal of Drugs in Dermatology

Volumn 14, Issue 12, 2015, Pages 1394-1399

  Gold, Linda F Stein ^a   Spelman, Lynda ^b   Spellman, Mary C ^c   Hughes, Matilda H ^d   Zane, Lee T ^d  

^a HENRY FORD HOSPITAL   (United States)

^b Veracity Clinical Research   (Australia)

^c Private Practice   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE; BORON DERIVATIVE; DERMATOLOGICAL AGENT; FUSED HETEROCYCLIC RINGS; IMMUNOSUPPRESSIVE AGENT; OINTMENT;

ADOLESCENT; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; ATOPIC DERMATITIS SEVERITY INDEX; BURN; CELLULITIS; CHILD; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THORAX PAIN; TONSILLITIS; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS INFECTION; BIOASSAY; CLINICAL TRIAL; DERMATITIS, ATOPIC; DOSE RESPONSE; OINTMENT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; CHILD; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; TREATMENT OUTCOME;

EID: 84988472794     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125-137.
2. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
4. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15.
5. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013;15(4):303-310.
6. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364-372.
7. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17-26.
8. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.
9. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10(11):1236-1242.
10. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19(8):2129-2132.
11. Freund YR, Akama T, Alley MR, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586(19):3410-3414.
12. Zane LT, Gogoleva T, Heerinckx FA, Jermano JA. Safety and efficacy of AN2728 and AN2898 ointments in a phase 2a bilateral study of mild-to-moderate atopic dermatitis. Poster presented at: Annual Meeting of the Society for Investigative Dermatology; May 9-12, 2012; Raleigh, NC.
13. Zane LT, Tom WL, Chanda S, Liu L, Van Syoc M. Safety, pharmacokinetics and efficacy of AN2728 ointment, 2% in a phase 2 study of adolescents with mild-to-moderate atopic dermatitis. Poster presented at: International Investigative Dermatology Meeting; May 8-11, 2013; Edinburgh, Scotland.
14. Kircik L, Call R, Tschen E, et al. Maximal use systemic exposure (MUSE) study evaluating AN2728 topical ointment, 2%, a boron-based small molecule for the treatment of mild-to-moderate atopic dermatitis in children 2 to 17 years of age. Poster presented at: Annual Meeting of the European Society for Dermatological Research; September 10-13, 2014; Copenhagen, Denmark.
15. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;60(Suppl 92):44-47.
16. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134(7):805-809.
17. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4):812-824.
18. Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008;155(3):308-315.